(Q41361742)

English

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies

scientific article published on 7 February 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 September 2017

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies (English)

1 reference

Europe PubMed Central

29 September 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

oncolytic virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Eleni M Karapanagiotou

1

1 reference

Europe PubMed Central

29 September 2017

Victoria Roulstone

2

1 reference

Europe PubMed Central

29 September 2017

Katie Twigger

3

1 reference

Europe PubMed Central

29 September 2017

Mercel Ball

4

1 reference

Europe PubMed Central

29 September 2017

Maryanne Tanay

5

1 reference

Europe PubMed Central

29 September 2017

Chris Nutting

6

1 reference

Europe PubMed Central

29 September 2017

Kate Newbold

7

1 reference

Europe PubMed Central

29 September 2017

Martin E Gore

8

1 reference

Europe PubMed Central

29 September 2017

James Larkin

9

1 reference

Europe PubMed Central

29 September 2017

Konstantinos N Syrigos

10

1 reference

Europe PubMed Central

29 September 2017

Matt Coffey

11

1 reference

Europe PubMed Central

29 September 2017

Brad Thompson

12

1 reference

Europe PubMed Central

29 September 2017

Karl Mettinger

13

1 reference

Europe PubMed Central

29 September 2017

Richard G Vile

14

1 reference

Europe PubMed Central

29 September 2017

Hardev S Pandha

15

1 reference

Europe PubMed Central

29 September 2017

Geoff D Hall

16

1 reference

Europe PubMed Central

29 September 2017

Alan A Melcher

17

1 reference

Europe PubMed Central

29 September 2017

John Chester

18

1 reference

Europe PubMed Central

29 September 2017

Kevin J Harrington

19

1 reference

Europe PubMed Central

29 September 2017

language of work or name

0 references

publication date

7 February 2012

1 reference

Europe PubMed Central

29 September 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

29 September 2017

18

1 reference

Europe PubMed Central

29 September 2017

2080-2089

1 reference

Europe PubMed Central

29 September 2017

7

1 reference

Europe PubMed Central

29 September 2017

A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

Tumor infection by oncolytic reovirus primes adaptive antitumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

Reovirus activates human dendritic cells to promote innate antitumor immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

1 October 2017

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

11 June 2018

A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

19 August 2018

Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

19 August 2018

Reovirus infections in human volunteers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

19 August 2018

Prevalence of Reovirus‐Specific Antibodies in Young Children in Nashville, Tennessee

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5553618

30 September 2018

A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22316603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/22316603

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-11-2181

1 reference

Europe PubMed Central

29 September 2017

1 reference

Europe PubMed Central

29 September 2017

1 reference

Europe PubMed Central

29 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41361742&oldid=2096647869"